PeterHaanJohnsonMD

Breast Cancer, Gastrointestinal Cancer, Hematologic Oncology, Thoracic Cancer

Medical Oncologist/Hematologist

Dr. Johnson is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2004 - 2007
Beth Israel Deaconess Medical CenterResidency, Internal Medicine, 2001 - 2004
University of Kentucky College of MedicineClass of 2001
Princeton UniversityB.A., Ecology and Evolutionary Biology, 1993 - 1997

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
Merit Award American Society of Clinical Oncology Foundation, 2005
Academic Excellence Scholarship University of Kentucky College of Medicine, 2001
Beale Family Practice Scholarship University of Kentucky College of Medicine, 1997
National Merit Scholar Finalist 1993
Join now to see all

PubMed

3 citations
The use of HER2 modulation in the adjuvant setting.
Peter H. Johnson, Francisco J. Esteva
Current Oncology Reports. 2007-01-01
232 citations
Treatment of pregnant breast cancer patients and outcomes of children exposed to chemotherapy in utero
Karin M. E. Hahn, Peter H. Johnson, Nancy Gordon, Henry Mark Kuerer, Lavinia P. Middleton
Cancer. 2006-09-15

Journal Articles

Vorinostat and Bortezomib as Third-Line Therapy in Patients with Advanced Non-Small Cell Lung Cancer: A Wisconsin Oncology Network Phase II Study
Tien Hoang, Toby C. Campbell, Chong Zhang, KyungMann Kim, Jill M. Kolesar, Kurt R. Oettel, Jules H. Blank, Emily G. Robinson, Harish G. Ahuja, Ron J. Kirschling, Peter..., Investigational New Drugs, 6/1/2013
The Use of HER2 Modulation in the Adjuvant Setting
Peter H. Johnson and Francisco J. Esteva, Current Oncology Reports, 1/1/2007
Update on Approaches to the treatment of non-small-cell lung cancer
P.H. Johnson and E.S. Kim, Oncology, 1/1/2005

Abstracts/Posters

Nuclear staining of topoisomerase II (topo II) may predict response to anthracycline but not to taxane based neoadjuvant chemotherapy regimens.
Peter Johnson, Savitri Krishnamurthy, Aman Buzdar, Gabriel Hortobagyi, Stacy Moulder, Breast Cancer Research and Treatment, 12/1/2006
The Treatment of Pregnant Women with Breast Cancer and the Outcomes of the Children Exposed to Chemotherapy In Utero.
P. Johnson, K.Gwyn, N. Gordon, L. Middleton, H. Kuerer, G. Perkins, W. Yang, G. Hortobagyi, R. Theriault, Journal of Clinical Oncology; 2005 Meeting of the American Society of Clinical Oncology, 1/1/2005

COVID-19 Vaccination May Offer Less Effective and Shorter-Lasting Protection for Some Cancer PatientsJune 7th, 2022
Your Guide to the Top Doctors in the Milwaukee AreaJune 1st, 2022
Population-Scale Study Highlights Ongoing Risk of COVID-19 in Some Cancer Patients Despite VaccinationMay 24th, 2022
Join now to see all